Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or Adolescents
To evaluate the efficacy and safety of pazopanib combined with TGI/CIV chemotherapy in children and adolescents with recurrent or refractory rhabdomyosarcoma.
Rhabdomyosarcoma, Recurrent, Refractory
DRUG: pazopanib|DRUG: TGI chemotherapy|DRUG: CIV chemotherapy
Objective Response Rate(ORR), Defined as the proportion of patients who achieved complete response (CR) and partial response (PR) according to RECIST v1.1, Up to 4 cycles of chemotherapy (each cycle is 21 days)
Disease control rate (DCR), Refers to the percentage of patients with confirmed complete response, partial response, and disease stability in patients with evaluable efficacy, Up to 4 cycles of chemotherapy (each cycle is 21 days)|Incidence of adverse events, Use NCI-CTCAE version 5.0 for classification and grading, Up to 4 cycles of chemotherapy (each cycle is 21 days)
To evaluate the efficacy and safety of pazopanib combined with TGI/CIV chemotherapy in children and adolescents with recurrent or refractory rhabdomyosarcoma.